36
Participants
Start Date
November 4, 2019
Primary Completion Date
January 10, 2020
Study Completion Date
January 31, 2020
0.5mg AZ-010; placebo
Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
1mg AZ-010
Subject will receive a single inhaled dose (1.0 mg) of AZ-010 or matching Staccato Placebo
3mg AZ-010
Subject will receive a single inhaled dose (3.0 mg) of AZ-010 or matching Staccato Placebo
AZ-010 1mg
2-period, 2-treatment open-label crossover design
IV Granisetron 1mg
2-period, 2-treatment open-label crossover design
Placebo
Participants in Part A, Cohorts 1, 2, and 3, double-blind, randomized, and placebo-controlled study who received placebo.
Celerion, Tempe
Lead Sponsor
Collaborators (1)
Celerion
INDUSTRY
Alexza Pharmaceuticals, Inc.
INDUSTRY